Dyne Therapeutics (DYN) Institutional Ownership

96.68% of Dyne Therapeutics' stock is owned by institutional investors. Learn more on DYN's institutional investor holdings.

Of the 230 institutional investors that purchased Dyne Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: T. Rowe Price Investment Management Inc. ($15.95M), Adage Capital Partners GP L.L.C. ($4.81M), Orbis Allan Gray Ltd ($4.80M), Vanguard Group Inc. ($4.27M), Vestal Point Capital LP ($3.85M), FMR LLC ($3.71M), and RA Capital Management L.P. ($3.67M).

Institutional investors have bought a total of 78,500,337 shares in the last 24 months. This purchase volume represents approximately $1.26B in transactions.

Of the 64 institutional investors that sold Dyne Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Vestal Point Capital LP ($2.66M), Siren L.L.C. ($2.50M), Marshall Wace LLP ($2.34M), Braidwell LP ($2.14M), Logos Global Management LP ($1.15M), Janus Henderson Group PLC ($1.10M), and Vivo Capital LLC ($1.06M).

Institutional investors have sold a total of 17,756,016 shares in the last 24 months. This volume of shares sold represents approximately $319.05M in transactions.